ALNY
ALNYLAM PHARMACEUTICALS, INC.
Key Financials
Operating Income
$501.6M
↑ 383.6%
Revenue
$3.7B
↑ 65.2%
Net Income
$313.7M
↑ 55.2%
Total Assets
$5.0B
↑ 17.1%
Total Liabilities
$4.2B
↑ 0.1%
EPS (Diluted)
$2.33
↑ 54.3%
Shareholders' Equity
$789.2M
↑ 1076.3%
Cash & Equivalents
$1.7B
↑ 71.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 10/2/2026 | View on SEC |
| 4 | 9/22/2026 | View on SEC |
| 10-Q | 7/30/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 3 | 6/3/2026 | View on SEC |
| 144 | 6/1/2026 | View on SEC |
| 8-K | 5/27/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALNY |
| Company Name | ALNYLAM PHARMACEUTICALS, INC. |
| CIK | 1178670 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (617) 551-8200 |